Cambridge Investment Research Advisors

Cambridge Investment Research Advisors’s Vir Biotechnology VIR Stock Holding History

Cambridge Investment Research Advisors’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$93K	Hold	10,355	–	–	﹤0.01%	3804
2025 Q4	$62K	Buy	+10,355	New	+$61.7K	﹤0.01%	3743
2022 Q4	–	Sell	-11,426	Closed	-$220K	–	3217
2022 Q3	$220K	Buy	+11,426	New	+$290K	﹤0.01%	2624
2022 Q1	–	Sell	-10,225	Closed	-$428K	–	3322
2021 Q4	$428K	Sell	10,225 -4,565	-31%	-$179K	﹤0.01%	2240
2021 Q3	$644K	Buy	14,790 +4,270	+41%	+$185K	﹤0.01%	1848
2021 Q2	$497K	Buy	10,520 +150	+1%	+$6.82K	﹤0.01%	2070
2021 Q1	$532K	Buy	+10,370	New	+$559K	﹤0.01%	1865

Other funds holding VIR

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

GSK plc London $599M AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $1.66B AUM 340.85% 1-Year Est. Return